Company Description
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.
It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates.
The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024.
XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Owen Hughes |
Contact Details
Address: 2200 Powell Street, Suite 310 Emeryville, California 94608 United States | |
| Phone | 510 204 7200 |
| Website | xoma.com |
Stock Details
| Ticker Symbol | XOMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000791908 |
| CUSIP Number | 98419J206 |
| ISIN Number | US98419J2069 |
| Employer ID | 52-2154066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Owen P. Hughes Jr. | Chief Executive Officer and Director |
| Thomas M. Burns | Senior Vice President of Finance and Chief Financial Officer |
| Brad Sitko | Chief Investment Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 17, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 8-K/A | [Amend] Current report |
| Jan 28, 2025 | SCHEDULE 13D/A | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 22, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |